DrugDashboards

Pantoprazole Sodium

Pantoprazole Sodium · PANTOPRAZOLE SODIUM 40 mg/1 · Injection, Powder, For Solution · Wasserburger Arzneimittelwerk GmbH

NDC 62287-0923-40 · 186 VIAL in 1 TRAY / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

This is a bulk ingredient, not a dispensable product — it is a raw material sold to manufacturers and compounders, so no plan prices it.

How Part D pricing works →

NADAC price per unit

ⓘ How this was built
Data sources
  • CMS NADAC weekly files (data.medicaid.gov), December 2024 onward
  • CMS NADAC per-year archive files, 2013 – November 2024, averaged per month
  • CMS Federal Upper Limit file — weighted average manufacturer price (WAMP) of the generic group (dashed line)
Method

One line, two regimes: before December 2024 each point is the average of that month's archived NADAC rows for this NDC; from December 2024 each point is a row from the weekly file, which CMS publishes only when the price changes, so the line holds flat until the next change and is extended to today when the last row is under 6 months old. Since the December 2024 file CMS computes generic NADAC as a 3-month moving average, so recent generic moves are smoothed and lag the market. The dashed WAMP is the manufacturer-side average for the whole multiple-source group, not this NDC alone. To check a point: open the NADAC file for that date on data.medicaid.gov and find this NDC.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NDCs that have a NADAC price and a generic name.

90-day shortage risk (model v2)

0.7%chance of a new FDA shortage posting for pantoprazole sodium (injectable) in the next 90 days

sterile injectable · price up 28% YoY · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

ⓘ How this was built
Data sources
  • FDA NDC Directory labeler counts, CMS NADAC price trend, openFDA shortages and enforcement, FDA inspection classifications, Wayback archive of FDA's shortage list (labels)
Method

A logistic regression over molecule × dosage-form markets, trained on a monthly grid of historical dates since 2019 with labels equal to whether a new FDA shortage posting appeared within the following 90 days; eight features knowable on each date (labeler count, sole-source flag, NADAC year-over-year change, Class I/II recalls, injectable form, discontinuation filings, open shortage episodes, recent OAI inspection). The probability shown is the model's output for today's feature values; the reasons are the features pushing this market's probability up, listed only when the feature actually holds here. Held-out performance and coefficients are on the fragility page.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $12.94 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
—
TE code
—
Approval date
—
Patents / exclusivity
—
ⓘ How this was built
Data sources
  • FDA Orange Book data files — patent and exclusivity tables for application (none), edition retrieved 2026-08-24
Method

Rows are the Orange Book's patent and exclusivity listings for this NDA, de-duplicated across product numbers (the file repeats a listing for every strength). A listed patent is a claim the sponsor filed; it may cover a use rather than the molecule, may be challenged, and may be delisted — a listing is not proof a generic is blocked. Pediatric extensions appear as *PED rows. FDA blocks automated downloads of the Orange Book from cloud servers, so the edition can trail FDA's monthly release; the retrieval date above is the edition shown. To check: search the application number on FDA's Orange Book site.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Shortage history

ⓘ How this was built
Data sources
  • FDA drug shortages via openFDA (current file: Current, To Be Discontinued, and recently Resolved rows)
  • Internet Archive (Wayback) snapshots of FDA's shortage list since 2019, reconstructed into episodes
  • DrugDashboards Kaplan–Meier duration curves and conditional duration model
Method

Top rows are FDA's live listings whose package NDC is this product or another package of the same generic name and dosage form. openFDA drops resolved rows after about six months, so older episodes come from monthly Wayback snapshots of FDA's file, matched on the molecule with dosage-form words stripped (that matching can pull in other salts or forms of the same molecule — the presentation is shown so you can tell). 'Month N of a typical M' compares this episode's age with the Kaplan–Meier median for its form class (injectable, oral solid, other) over episodes since October 2019, open episodes censored; the resolution odds come from a model conditioned on the episode's age and reason. To check: FDA's drug shortage database, and web.archive.org for its history.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Not on FDA's current shortage list. Archived episodes below.

Archived episodes (FDA list history via Wayback, 2019+)
  • Planned discontinuation — Sun Pharmaceutical Industries Limited, Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-40) (listed as “Pantoprazole Sodium Injection”)Dec 5, 2024 → last seen Aug 3, 2025
  • Planned discontinuation — Sun Pharmaceutical Industries Limited, Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-45) (listed as “Pantoprazole Sodium Injection”)Dec 5, 2024 → last seen Aug 3, 2025
  • Planned discontinuation — Sun Pharmaceutical Industries Limited, Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-44) (listed as “Pantoprazole Sodium Injection”)Dec 5, 2024 → last seen Aug 3, 2025
  • Shortage ended — Sandoz Inc., Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 65219-433-15) (listed as “Pantoprazole Sodium Injection”)Jun 4, 2019 → Sep 15, 2023
  • Shortage ended — Sandoz Inc., Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 0781-3232-95) (listed as “Pantoprazole Sodium Injection”)Jun 4, 2019 → Sep 15, 2023
  • Shortage ended — Sandoz Inc., Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 72572-550-10) (listed as “Pantoprazole Sodium Injection”)Jun 4, 2019 → Sep 15, 2023
  • Shortage ended — Hospira, Inc., a Pfizer Company, Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-0923-60) (listed as “Pantoprazole Sodium Injection”)May 28, 2019 → Sep 15, 2023
  • Shortage ended — Hospira, Inc., a Pfizer Company, Protonix Iv, Injection, 40 mg/10 mL (NDC 0008-0923-55) (listed as “Pantoprazole Sodium Injection”)May 28, 2019 → Sep 15, 2023

Showing 8 of 30 archived episodes.

Recalls (this NDC)

ⓘ How this was built
Data sources
  • FDA drug enforcement reports via openFDA
Method

Enforcement reports whose product NDC list includes this exact package NDC, newest first, with FDA's classification (I = reasonable probability of serious harm, II = temporary or reversible harm, III = unlikely to cause harm) and the recall's current status. Reports for other packages of the same drug are not shown here; 275 of the last year's Class I/II reports carry no NDC at all and cannot be matched. To check: search the recall number on openFDA or FDA's enforcement reports.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No enforcement reports list this package NDC.

Labelers of Pantoprazole Sodium (Injection, Powder, For Solution)

13 labelers active in the last 30 days, of which 1 is a repackager; 0not seen for 30+ days. Keyed on FDA's generic-name string — other salts or forms of the molecule are separate rosters.

ⓘ How this was built
Data sources
  • FDA NDC Directory (openFDA), read daily since 2026-07-15 — labeler_name per package
  • DailyMed SPL establishment roles + name patterns → derived.labeler_kinds (repackager / manufacturer / unknown)
Method

One row per labeler that lists any package with this exact generic-name string and dosage form; strengths are combined. 'First seen' is the first daily snapshot that contained the labeler here (2026-07-15 for everything present at the start), 'last seen' the most recent; a labeler counts as active when seen in the last 30 days. Repackagers and relabelers are flagged when their own labels show only repack/relabel operations or their name matches a known repackager, and are excluded from every 'makers' count on this page. Listing is not volume: a labeler with a listed NDC may ship little or nothing. To check: search the generic name in FDA's NDC Directory and list the labelers.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

LabelerStrengthsFirst seenLast seen
Meitheal Pharmaceuticals Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 3, 2026
BE Pharmaceuticals Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.PANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCrepackagerPANTOPRAZOLE SODIUM 40 mg/1; PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Devatis Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Eugia US LLCPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Northstar Rx LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Novadoz Pharmaceuticals LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Piramal Critical CarePANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Sandoz IncPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Takeda GmbHPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Wasserburger Arzneimittelwerk GmbHPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 15, 2026.

Cite this page

DrugDashboards, "Pantoprazole Sodium — NDC 62287-0923-40," retrieved September 4, 2026, https://drugdashboards.com/drug/62287092340.

Free to cite with attribution — see how the data is put together.